Shanghai Allist Pharmaceuticals Co. Ltd. A (SHG:688578) — Market Cap & Net Worth
Market Cap & Net Worth: Shanghai Allist Pharmaceuticals Co. Ltd. A (688578)
Shanghai Allist Pharmaceuticals Co. Ltd. A (SHG:688578) has a market capitalization of $7.93 Billion (CN¥54.18 Billion) as of August 16, 2026. Listed on the SHG stock exchange, this China-based company holds position #2660 globally and #326 in its home market, demonstrating a 8.74% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Allist Pharmaceuticals Co. Ltd. A's stock price CN¥120.40 by its total outstanding shares 450000000 (450.00 Million). See 688578 net asset quality score to understand what proportion of total assets are financed by equity.
Shanghai Allist Pharmaceuticals Co. Ltd. A Market Cap History: 2020 to 2026
Shanghai Allist Pharmaceuticals Co. Ltd. A's market capitalization history from 2020 to 2026. Data shows growth from $1.85 Billion to $7.93 Billion (22.37% CAGR). Also see 688578 total asset value for a full breakdown of the balance sheet.
Shanghai Allist Pharmaceuticals Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Allist Pharmaceuticals Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Shanghai Allist Pharmaceuticals Co. Ltd. (688578) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.33x
Shanghai Allist Pharmaceuticals Co. Ltd. A's market cap is 1.33 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.14x
Shanghai Allist Pharmaceuticals Co. Ltd. A's market cap is 3.14 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.85 Billion | $560.89K | -$310.52 Million | 3302.84x | N/A |
| 2021 | $1.96 Billion | $530.09 Million | $18.27 Million | 3.71x | 107.49x |
| 2022 | $1.28 Billion | $791.00 Million | $130.52 Million | 1.62x | 9.81x |
| 2023 | $2.71 Billion | $2.02 Billion | $644.17 Million | 1.34x | 4.21x |
| 2024 | $3.94 Billion | $3.56 Billion | $1.43 Billion | 1.11x | 2.76x |
| 2025 | $6.86 Billion | $5.17 Billion | $2.18 Billion | 1.33x | 3.14x |
Competitor Companies of 688578 by Market Capitalization
Companies near Shanghai Allist Pharmaceuticals Co. Ltd. A in the global market cap rankings as of August 16, 2026. Also see cash efficiency ratio of Shanghai Allist Pharmaceuticals Co. Ltd. for how efficiently the company converts equity into cash flow.
Key companies related to Shanghai Allist Pharmaceuticals Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #431 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #545 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- Samsung Biologics Co Ltd (KO:207940): Ranked #557 globally with a market cap of $48.56 Billion USD ( ₩71.66 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $505.75 |
| #431 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $803.48 |
| #545 | Argen-X | BR:ARGX | $49.55 Billion | €730.20 |
| #557 | Samsung Biologics Co Ltd | KO:207940 | $48.56 Billion | ₩1548000.00 |
Shanghai Allist Pharmaceuticals Co. Ltd. A Historical Marketcap From 2020 to 2026
Between 2020 and today, Shanghai Allist Pharmaceuticals Co. Ltd. A's market cap moved from $1.85 Billion to $ 7.93 Billion, with a yearly change of 22.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥7.93 Billion | +15.60% |
| 2025 | CN¥6.86 Billion | +73.87% |
| 2024 | CN¥3.94 Billion | +45.56% |
| 2023 | CN¥2.71 Billion | +111.69% |
| 2022 | CN¥1.28 Billion | -34.83% |
| 2021 | CN¥1.96 Billion | +6.04% |
| 2020 | CN¥1.85 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 15th, 2026 the market cap of Shanghai Allist Pharmaceuticals Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.93 Billion USD |
| MoneyControl | $7.93 Billion USD |
| MarketWatch | $7.93 Billion USD |
| marketcap.company | $7.93 Billion USD |
| Reuters | $7.93 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai Allist Pharmaceuticals Co. Ltd. A
Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company's lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl c… Read more